Advancements in Plasma Biomarkers for Alzheimer's Diagnosis

Plasma biomarker tests, particularly phosphorylated tau 217 (PT217), have shown high accuracy in identifying Alzheimer's disease pathology. Recent studies revealed that these tests performed with approximately 90% accuracy in both primary and secondary care settings. Notably, the accuracy of primary care physicians in diagnosing Alzheimer's without the biomarker test was significantly lower, at 61%, underscoring the need for these tools in clinical practice. While the biomarker tests are available commercially, there is a pressing need for education and guidelines for primary care physicians before widespread implementation.